BeiGene
BGNE
$187.49
Share price
0.29%
Change (1 day)
-2.15%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Revenue for BeiGene (BGNE)
Revenue in 2023 (TTM): $2.20 B
According to BeiGene 's latest financial reports the company's current revenue (TTM) is $2.20 B. In 2022 the company made a revenue of $1.41 B an increase over the years 2021 revenue that were of $1.17 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BeiGene from 2015 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $2.20 B | 55.69% |
| 2022 | $1.41 B | 20.37% |
| 2021 | $1.17 B | 280.83% |
| 2020 | $0.30 B | -27.87% |
| 2019 | $0.42 B | 116.03% |
| 2018 | $0.19 B | -16.85% |
| 2017 | $0.23 B | 22179.16% |
| 2016 | $1.07 M | -87.86% |
| 2015 | $8.81 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $0.86 B | -60.67% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $0.22 M | -99.99% | 🇺🇸 USA |